2018-003354-24
A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184)
Exelixis, Inc.·EU Clinical Trials RegisterOngoing
Study focus
- Disease/Condition
- Hepatocellular carcinoma
Sponsor & location
- Primary sponsor
- Exelixis, Inc.
- Funder
- Exelixis, Inc
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
- Known Fibrolamellar carcinoma, sarcomatoid HCC or mixed hepatocellular cholangiocarcinoma.
ICD-10 classifications
Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2018-003354-24
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2018-003354-24 through Pure Global AI's free database. This phase not specified trial is sponsored by Exelixis, Inc. and is currently Ongoing. The study focuses on Hepatocellular carcinoma.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.